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Strengths and limitations of this study
 ► This multistep and consensus- based study elabo-
rated quality standards reflecting minimal require-
ments for the safe and resident- oriented medication 
in nursing homes.
 ► The Delphi study was designed according to estab-
lished methodologies and used common indicators 
for consensus.
 ► The panel consisted of a large interprofessional 
group of experts from science and practice of which 
100% responded in both rounds.
 ► As the Delphi panel was composed only of Swiss ex-
perts, generalisability to other countries and health-
care systems needs to be carefully checked.
AbStrACt
Objectives The aim of the study was to develop quality 
standards reflecting minimal requirements for safe 
medication processes in nursing homes.
Design In a first step, relevant key topics for safe 
medication processes were deducted from a systematic 
search for similar guidelines, prior work and discussions 
with experts. In a second step, the essential requirements 
for each key topic were specified and substantiated with a 
literature- based rationale. Subsequently, the requirements 
were evaluated with a piloted, two- round Delphi study.
Setting Nursing homes in Switzerland.
Participants Interprofessional panel of 25 experts from 
science and practice.
Primary and secondary outcome measures Each 
requirement was rated for its relevance for a safer and 
resident- oriented medication on a 9- point Likert- Scale 
based on the RAND/UCLA method. The requirements were 
considered relevant if, in the second round, the median 
relevance rating was  ≥7 and the proportion of ratings ≥7 
was ≥80%.
results Five key topics with a total of 87 requirements 
were elaborated and rated in the Delphi study. After 
the second round (response rate in both rounds 100%), 
85 requirements fulfilled the predefined criteria and 
were therefore included in the final set of quality 
standards. The five key topics are: (I) ‘The medication 
is reviewed regularly and in defined situations’, (II) ‘The 
medication is reviewed in a structured manner’, (III) ‘The 
medication is monitored in a structured manner’, (IV) ‘All 
healthcare professionals are committed to an optimal 
interprofessional collaboration’ and (V) ‘Residents are 
actively involved in medication process’.
Conclusions We developed normative quality standards 
for a safer and resident- oriented medication in Swiss 
nursing homes. Altogether, 85 requirements define the 
medication processes and the behaviour of healthcare 
professionals. A rigorous implementation may support 
nursing homes in taking a step towards safer and 
resident- oriented medication.
bACkgrOunD
Polypharmacy and potentially inappro-
priate prescribing (PIP) are increasingly 
prevalent in Swiss nursing homes as they 
are internationally.1 2 Polypharmacy may be 
associated with adverse drug events (ADE)3 
and with every additional drug prescribed 
the risk for problems related to medication 
increases.4 The occurrence of PIP poses an 
additional risk for ADE.5 6
The causes of ADE were evaluated in two 
large Canadian nursing homes.7 The study 
found that errors associated with prevent-
able ADE mainly occurred at the medication 
prescribing and monitoring stages. Targeting 
these process stages in efforts to optimise the 
residents’ medication may thus contribute 
to reducing ADE. In fact, many intervention 
studies have successfully implemented new 
processes concerning the prescribing and 
monitoring stages or tools to nursing home 
staff to optimise medication and medication- 
related safety. The implementation of medi-
cation reviews,8 structured monitoring of the 
resident and their medication9 10 and the use 
of PIP- lists11 have for example shown benefits.
The implementation of such interven-
tions in Switzerland is however scarce. With 
an online survey among directors of Swiss 
nursing homes in 2017, we assessed how 
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widely safety- relevant medication processes are already 
implemented.12 13 Of 420 participants, 35% stated that 
their institution does not perform regular medication 
reviews, 91% do not use a PIP- list and 93% have no 
standardised process to monitor side effects. We found 
that the implementation of these processes is hetero-
geneous and is associated with certain organisational 
characteristics. Nursing homes with low implementa-
tion of the processes in question often collaborated 
with several external family physicians and they were 
predominantly located in the German- speaking regions 
of Switzerland. A more homogeneous implementation 
of processes may partly be hindered by federalism, as 
a overview article on medication safety in Switzerland 
outlines.14 Regionally different law impairs nationally 
equal care practice.
The national programme ‘progress! Medication safety 
in nursing homes’ aims to promote a safer and resident- 
oriented medication of Swiss nursing home residents. 
In the context of this programme, safe medication is 
defined as a drug therapy with well balanced risks and 
benefits. Specifically, the inappropriate use of polyphar-
macy should be addressed and PIP should be reduced. 
The residents’ preferences should be respected by 
actively involving them in decision making. To achieve the 
programme goal, we sought to implement pre- existing 
practice guidelines describing processes for medication 
prescribing and monitoring. However, we did not find 
any guidelines that focused on the processes of interest, 
were precise enough, were applicable to Swiss nursing 
homes and addressed the whole interprofessional team.
Therefore, the goal of this study was to develop norma-
tive quality standards for safe medication in Swiss nursing 
homes. The quality standards should describe minimal 
requirements for prescribing, monitoring and reviewing 
medication in nursing homes. They should not provide 
guidance on drug choices in specific illness. In addition, 
they should not describe structural or outcome quality, 
nor be meant to measure quality, as quality indicators do.15 
Lastly, the quality standards should address all healthcare 
professionals involved in the medication processes in 
nursing home residents, namely nurses, pharmacists and 
physicians. If rigorously implemented, the quality stan-
dards should contribute to a safer and resident- oriented 
medication in nursing homes.
MethODS
The quality standards were developed in three steps. First, 
we started with a systematic literature search in autumn 
2018. Second, we developed key topics to be covered by 
the quality standards and drafted a first set of minimal 
requirements supported by evidence- based rationales. 
The ‘key topics’ together with their ‘requirements’ repre-
sent the ‘quality standards’. Third, we used a Delphi 
consensus study to develop the final set of requirements 
in autumn 2019.
Systematic literature search
In a first step, we searched for practice guidelines for 
healthcare professionals describing good prescribing or 
medication review practice. We defined the following 
inclusion criteria: published no more than 10 years ago 
(2008–2018); published in English, German or French; 
report details of guideline development; and explic-
itly address the medication of nursing home residents 
or elderly patients. The search was conducted in three 
databases PubMed, Cinahl and Embase (search terms see 
online supplemental additional file 1) to identify scientif-
ically developed and published guidelines.
The search was repeated in 16 guideline databases 
to find guidelines that were not published in scientific 
journals. The databases were known by the project team 
or found through unsystematic web search. They were 
mainly from Switzerland, Germany, UK, USA, Canada 
and Australia. The same or synonymous terms as for the 
scientific databases were used and translated if needed. 
In databases where no free text search was possible, docu-
ment titles were screened. In this case, the documents 
were not preselected by search terms, therefore, it was not 
possible to count the total of screened documents from 
guideline databases.
Development of key topics and requirements
After the literature search, the project team consisting 
of a physician, a pharmacist, a nurse, a research asso-
ciate, and a senior researcher developed the key topics 
to be covered. The key topics were deduced from three 
different sources. First, the two guidelines found in the 
systematic search (see results section) informed the range 
of topics to address. Second, knowledge gained from the 
first part of the national programme ‘progress! Medica-
tion safety in nursing homes’, which included an online 
survey conducted among nursing home directors12 13 16 17 
and explorative interviews with 12 physicians provided 
information on the appropriateness of the topics.18 The 
findings from these studies pointed to a significant poten-
tial for improvement, most importantly in reviewing and 
monitoring the medication of nursing home residents in 
a more structured way. Furthermore, it became clear that 
the key topics also had to not only cover the collabora-
tion between healthcare professionals, but also address 
the integration of residents. With these insights in mind, 
a first draft of five key topics was developed by the project 
team. Third, these drafts were discussed and counter-
checked in informal and unstructured ways with experts 
of various professions to ensure their practical relevance.
For each of the key topics, several specific requirements 
were elaborated by the project team. The requirements 
describe more precisely what should be done by nursing 
home staff or what needs to be in place within the organi-
sation to meet the key topic. To draft these requirements, 
the project team searched evidence pertinent to each key 
topic and of highest possible evidence level. In addition, 
different practice guidelines informed the definition of 
the requirements. The evidence for each key topic was 
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summarised in a rationale to justify the suggested require-
ments. This first set of requirements was submitted for 
evaluation by the following Delphi panel.
Delphi preparation
Delphi panel members were purposefully selected to repre-
sent a wide range of expertise. Members of all healthcare 
professional groups addressed by the quality standards 
(physicians, pharmacists, nurses) were eligible as panellists 
if they had a comprehensive knowledge of geriatric medica-
tion. They had to be either researcher in the field of interest 
or practitioner working in nursing homes. The Delphi panel 
was required to represent all three main Swiss language 
regions (German, French, Italian), but the panellists had to 
be fluent in German or French to perform the Delphi. In 
addition, two experts in quality management and/or patient 
safety were enlisted for each language region. Retired profes-
sionals were not eligible. Members of the programme’s advi-
sory group and other experts known to the project team were 
contacted for participation. In addition, professional associa-
tions were asked to suggest representatives. Potential experts 
were contacted by email to obtain their consent to partici-
pate. With their consent, panellists agreed that their names 
and affiliations would be published with the final quality 
standards, but they remained anonymous during the Delphi 
process.
The Delphi process was piloted to test clarity and feasi-
bility. Six professionals (one physician, two pharmacists, two 
nursing experts, one quality auditor) with practice experi-
ence and partly with research experience participated. Pilot 
participants received all documents as planned for the main 
Delphi rounds (see below) and were asked to complete 
the Delphi rating questionnaire sincerely. This allowed the 
project team to develop the evaluation method (ie, define a 
priori threshold rules, see below). Participants were informed, 
however, that their ratings would not be included in the final 
evaluation. Furthermore, participants were asked to provide 
feedback on the clarity and completeness of background 
information and instructions provided, and on any technical 
problems with the Delphi form, with rating or commenting. 
After the pilot, some minor adaptations were made to the 
documentation.
Delphi rounds
We performed a two- round Delphi study whose goal was 
to reach consensus about which requirements are relevant 
for a safer and resident- oriented medication of nursing 
home residents. The number of rounds was predefined, 
and no criteria were defined to stop the Delphi. The 
reporting is based on recommendations.19–21
For the first round, panellists received all necessary docu-
mentation by email. This included a description of the 
programme (background and aim), the purpose of quality 
standards and the methodology of their development, as well 
as a full version of the first set of quality standards including 
key topics, requirements (set 1) and rationales. In addition, 
the panellists received a modifiable excel sheet listing all the 
requirements to be rated and an instructional guide on how 
to complete the rating. They were asked to rate each require-
ment according to its relevance for a safer and resident- 
oriented medication. To support this, a guiding question 
was provided: ‘If this requirement is rigorously implemented 
in practice, how significant is its influence on a safer and 
resident- oriented medication?’. The instructional guide also 
provided definitions for ‘relevance’, for example, a require-
ment is highly relevant if its causal effect on the goal is large. 
Ratings were made on a 9- point Likert scale according to the 
RAND/UCLA Appropriateness Method,22 9 being highly 
relevant, 1 being not relevant at all. Panellists were informed 
that highly relevant requirements would be selected after 
the second round, without specifying what thresholds are 
applied. Panellists were asked to remain as consistent as 
possible in their ratings. Individual ratings were only visible 
to the project team, not to other panellists. In the first round, 
panellists had the possibility to add requirements (two empty 
lines per key topic) and to comment on the content, wording 
or on their own rating for each requirement. Abstentions 
should be avoided but they remained technically possible. 
The five key topics per se were not subject of the rating. In 
addition, panellists were explicitly asked not to consider feasi-
bility of implementation, that is, not dismiss clinically relevant 
requirements due to feasibility reasons.
The exact dates for the two Delphi rounds with dead-
lines were communicated to panel members beforehand, 
so that they could reserve time slots accordingly. The first 
round started on 30 September 2019, the second round 
started on 28 October 2019. Both rounds lasted 14 days, 
with a reminder sent on day 11 to all panellists not having 
sent in their ratings.
After the first round, requirements of set 1 were adapted 
according to predefined adaptation rules to form set 2. 
The rules concerned the level of relevance (LOR, ie, 
median of ratings) and the level of agreement (LOA, ie, 
proportion of all ratings being  ≥7). The following rules 
were defined: Requirements with an LOR≤3 and with 
≥80% of all ratings being  ≤3 were deleted for the second 
round. Ratings with a sufficiently high level of relevance 
(sLOR, defined as a median of ratings being  ≥7) and 
reaching a sufficiently high level of agreement (sLOA, 
defined as  ≥80% of all ratings are  ≥7) are only modified if 
comments suggest important changes. All other require-
ments were modified according to comments. Meta- level 
comments about the key topics overall or about structure 
were ignored. Suggestions for new requirements were 
reviewed and added to set 2 if appropriate.
For the second rating round, participants received an 
updated set of documents, namely the full version of the 
quality standards with requirements (set 2, modifications 
highlighted) and an updated version of the instructional 
guide. The guide now contained detailed information 
on the predefined thresholds that are applied for the 
evaluation. In the excel rating sheet, modifications were 
not highlighted, but aggregated results from the first 
rating round (LOR and LOA for each requirement) were 
displayed. For newly added or substantially amended 
requirements, no results were provided. In the second 
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Table 1 Composition of different sets of requirements throughout the Delphi
Key topic

















I: The medication is 
reviewed regularly and in 
defined situations
20 11 3* 6† 0 19 15
II: The medication is 
reviewed in a structured 
manner
38 30 6 2 2 40 39
III: The medication is 
monitored in a structured 
manner
13 8 3‡ 2 2‡ 15 14
IV: All healthcare 
professionals are 
committed to an optimal 
interprofessional 
collaboration
10 9 0 1 1 11 11
V: Residents are actively 
involved in medication 
process
6 5 1 0 0 6 6
Total 87 63 13 11 5 91 85
The five key topics with the number of their requirements are shown: Composition of requirements of set 1 (n=87) with their amendments 
after round 1, composition of set 2 (n=91) and the final set (n=85)
*One of those requirements was moved to the foreword, as it was a general remark, and therefore, was no longer part of the 
requirements.
†One of those requirements was not changed despite indication.
‡Two of those requirements reached sLOR and sLOA but were separated into four requirements (categorised as two changed and two 
new).
sLOA, sufficiently high level of agreement; sLOR, sufficiently high level of relevance.
round, no new requirement could be suggested. Panel-
lists were again asked to avoid (technically possible) 
abstentions.
To evaluate the second round, thresholds were defined 
a priori guided by literature.19–22 The following criteria 
were defined: Requirements were included in the final 
set if they reach sLOR and sLOA. In addition, require-
ments were only included in the final set if at least 1/3 of 
all panellists (=9 members) gave a rating. Ratings from 
all panellists were assigned equal weight. No limitation 




The literature search in scientific databases returned 
eight results for nursing home residents and 413 results 
for elderly patients (flow chart in online supplemental 
additional file 2). Of those 421 results, however, none 
of the papers met all inclusion criteria. Papers had to be 
excluded mainly because they reported observational or 
intervention studies or were focusing on a specific disease, 
drug or drug group. The search in guideline databases 
yielded one guideline for nursing home residents that 
met the inclusion criteria23 and two guidelines for older 
patients.24 25 One of those guidelines was not suitable for 
our purposes because of its structure according to medical 
indications and was therefore excluded a posteriori.25
In the end, two guidelines served as basis for the devel-
opment of our key topics.23 24 The German College of 
General Practitioners and Family Physicians published 
a text- book style guideline on polypharmacy in 2014, 
providing recommendations to family physicians on how 
to manage polypharmacy at each of the different stages 
in the medication process.24 The guideline advises what 
steps to take and what to consider while prescribing, 
reviewing or monitoring medication. The National Insti-
tute for Health and Care Excellence published a guide-
line on ‘managing medicines in care homes’ in 2014, 
which targets all professionals involved.23 This guide-
line encompasses good practice recommendations on 
prescribing and reviewing medicines, but it also covers 
other subjects such as handling and administering medi-
cation to residents.
Development of key topics and requirements
Five key topics with a first set of 87 requirements were 
developed (summarised in table 1 and provided in detail 
in online supplemental additional file 3). Subtitles were 
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Table 2 Characteristics of the 25 Delphi members, with the field they represent (science (s) or practice (p))
Language region Physicians Pharmacists Nurses Quality management
German 4 (1s, 3p) 2 (2s) 4 (2s, 2p) 1
French 1 (1s) 5 (2s, 3p) 4 (2s, 2p) 2
Italian 1 (1s) 1 (1p) 0 0
Total 6 (3s, 3p) 8 (4s, 4p) 8 (4s, 4p) 3
Panellists from quality management were not assigned to either science or practice.
not counted as requirement. This first set of quality stan-
dards was subsequently evaluated by the Delphi panel.
Delphi study
Twenty- five experts participated in the Delphi study. 
Their characteristics are shown in table 2. Response rate 
for both rounds was 100%.
The results of the first round are summarised in table 1 
and provided in detail in online supplemental additional 
file 3. After the first round, no requirement had an LOR 
of  ≤3 and a proportion of ratings ≤3 being  ≥80%. Of 
87 requirements, 76 (87%) reached the sLOR and sLOA 
thresholds. However, 13 of those needed amendment due 
to important comments. 11 requirements did not reach 
sLOR and/or sLOA and were revised except in one case 
where comments did not suggest specific changes and 
the requirement was already short and clear. Five new 
requirements were added. The median number of ratings 
given per requirement was 25.
In the second round, 91 requirements were rated 
(results summarised in table 1 and in detail with ratings 
for each requirement in online supplemental additional 
file 4). Of those, 85 requirements met predefined sLOR 
and sLOA criteria, thus were considered relevant and 
were included in the final set of quality standards. This 
was the case for all requirements of key topics IV and V. 
Six requirements in key topics I–III had to be removed 
from the final set, since they reached the sLOR but not 
the sLOA, that is, reached no consensus. The require-
ments were not further adapted, except minor changes 
in language for better understanding. The final set of 
quality standards, composed of five key topics with the 
requirements, is shown in the online supplemental addi-
tional file 4.
Consensus formed over the two rounds, as the median 
LOA was between 82% and 100% in first round and 
between 96% and 100% in second round. Median LOR 
for all key topics remained nine in both rounds.
DiSCuSSiOn
In this study, we developed quality standards for a 
safer and resident- oriented medication in nursing 
homes. They were elaborated in an evidence- based 
and consensus- based process for Swiss nursing home 
practice. The final quality standards consist of five key 
topics with 85 requirements, representing minimal 
standards for the behaviour of healthcare professionals 
and institutions. The five key topics identified are: (I) 
‘The medication is reviewed regularly and in defined 
situations’, (II) ‘The medication is reviewed in a struc-
tured manner’, (III) ‘The medication is monitored in a 
structured manner’, (IV) ‘All healthcare professionals 
are committed to an optimal interprofessional collabo-
ration’ and (V) ‘Residents are actively involved in medi-
cation process’.
Overall, the requirements reached very high relevance 
ratings and high LOA among the experts. The LOA 
increased between the first and second round and only 
a few requirements had to be excluded from the final 
set. Lowest LOA was seen in key topic I and most of the 
eliminated requirements belonged to this topic. A reason 
for this may be that some of its requirements describe 
behaviours that have not yet been widely implemented 
in current practice, for example, reviewing the medica-
tion after readmission from hospital. The ratings possibly 
reflect the perception that high quality resident care is 
already provided even without such time- consuming prac-
tices. Even if this requirement received low approval by the 
panel, it reached the needed thresholds. This confirms 
findings from literature, that medication is substantially 
amended during hospitalisation, contains more subop-
timal drugs and therefore may need special attention.26 27 
Four requirements of key topic I were finally rejected by 
the Delphi. One of these rejected requirements was the 
use of aggregated (rather than individual) data on medi-
cation for analyses, for example, to identify and target 
trends of suboptimal proton pump inhibitor use. The 
reluctance towards this approach is consistent with find-
ings from a Swiss intervention trial published after the 
Delphi was conducted.28 The intervention consisted of an 
analysis of population aggregated data followed by inter-
professional quality circles where professionals agreed 
on deprescribing strategies for specific drug classes. The 
intervention showed an inconclusive effect on the indi-
vidual medication overall, supporting expert ratings in 
our study. However, an effect of the intervention was seen 
in prescription rates of specific drug groups that were 
addressed in the quality circles, such as proton pump 
inhibitors. This indicates that drug class aggregated data 
may be useful for discussions around deprescribing in 
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Some of the requirements reaching sufficient but 
rather lower levels of agreement concerned the role of 
pharmacists. Evidence suggests that involving pharma-
cists in medication reviews can contribute to safe medi-
cation use.8 29 In Switzerland, however, pharmacists are 
not yet widely involved in medication reviews in nursing 
homes.12 16 This is partly due to heterogeneous regu-
lations concerning the (compulsory) collaboration 
between pharmacists and nursing homes, and the fact 
that in several regions, physicians can dispense medi-
cation to nursing home residents by themselves.12 The 
heterogeneity in current practice may have, therefore, 
influenced the ratings of Delphi panellists in regard to 
the pertinence of strengthening the pharmacists’ role.
The quality standards strongly emphasise the collab-
oration between different healthcare professionals and 
emphasise that ensuring medication safety is an inter-
professional task. Interprofessional collaboration has 
been found beneficial in reviewing and monitoring 
medication8–10 30 and may be a facilitating factor in 
enhancing medication safety.31 32 Our quality standards 
contain general rules for good collaboration, and also 
describe processes that should be performed together 
and/or build on the competencies and experiences of 
different professionals. When performing a medication 
review, for example, the pharmacist starts with a pharma-
ceutical analysis of the medication. Nurses in turn add 
their specific observations from daily care, for example 
changes in resident’s health status or potentially subop-
timal therapies. In a last step, the physician summarises 
and completes all drug related problems identified and 
develops an action plan. Due to the great emphasis to 
interprofessional care, our quality standards, therefore, 
address all healthcare professionals. This differentiates 
the standards from other guidelines on similar topics 
which address, for example, only pharmacists33 or family 
physicians.24
Another important aspect in our quality standards is 
that they highlight the importance of reviewing and opti-
mising drug therapy for all residents, even for residents 
without any acute problems. Medication reviews are often 
initiated only if something changes in the health status or 
care of a resident. Residents in stable health do not see a 
physician regularly and often, their medication remains 
unchanged as long as there are no substantial problems 
with the therapy. This is a circumstance that may lead to 
long- term use of potentially inappropriate medications.1 
Our quality standards, therefore, specifically define inter-
vals in which medication should be reviewed.
With this study, we aimed to develop what would 
be considered a ‘gold standard’ for safe medication 
processes, solely driven by its clinical relevance and not 
by feasibility arguments. In a next step, these quality 
standards will have to be implemented in practice. It is 
clear that uptake by front- line healthcare professionals 
will require time and effort. A stepwise implementation 
of single key topics or even single requirements may be 
helpful. Implementation can be enforced by regulation 
or facilitated by certification incentives. Furthermore, 
remuneration of certain of the suggested processes, such 
as performing regular medication reviews, is essential. A 
lack of remuneration is considered to be an important 
reason why healthcare practitioners were so far reluctant 
to perform them. For implementation success, accep-
tance by the target group is a prerequisite. As we involved 
the affected professional groups and practitioners from 
the field, we expect that acceptance of the standards can 
be achieved. To assess adherence to the quality standards 
(ie, what should be done), valid and reliable process indi-
cators (ie, what is being done) must first be operation-
alised. The quality standards are normative and are not 
specific enough to serve as process or outcome indica-
tors. Outcome indicators (ie, what has been achieved) 
are already established in nursing homes.15 One of these 
outcome indicators is ‘polypharmacy’, that is, the propor-
tion of residents taking nine or more drugs during the 
last 7 days.
There are some limitations regarding the content of 
the quality standards. They focus only on some aspects of 
patient care, namely medication review and monitoring. 
In comparison, other guidelines include a much broader 
range of additional processes such as prescribing, remote 
prescribing by telephone or storage of drugs.23 Our quality 
standards do not provide guidance on which medication 
to prescribe in specific cases, nor do they alert profes-
sionals of possibly harmful situations, as other guidelines 
do.24 Furthermore, they do not address diagnostics and 
routine and mandatory prescription validation when the 
pharmacist fills the prescription. Lastly, there are clin-
ical situations in which it is not appropriate to follow our 
quality standards, for example, in end- of- life care.
The study must also be viewed in light of some meth-
odological strengths and limitations. We performed a 
systematic literature search in 19 different databases, but 
very few relevant publications were found. Consulting 
additional guideline databases, for example from more 
different countries, could have been useful to detect other 
guidelines relevant to our work. The Delphi method is an 
established consensus finding method which goes beyond 
individual rating and in fact, consensus was built over the 
two rounds in our study. We designed the Delphi process 
according to established methodologies,22 performed a 
common and feasible number of rounds19 and used estab-
lished indicators for consensus (median score of ratings 
and percentage of agreement).20 Also, the above- average 
number of panellists20 and their complete response rates 
in both rounds provided additional strength to our Delphi 
study. The selection of panel members may have been too 
convenient. However, as Switzerland is a small country, 
recruiting a large panel with experts independent of our 
national organisation and our large national programme 
was challenging. Many experts had been involved in the 
programme before and thus may have rated the require-
ments too positively. The recruitment of sufficient experts 
for the smaller Italian speaking part of Switzerland was 
not possible. But the still geographically quite dispersed 
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panel is important to represent different national and 
professional cultures and may increase applicability of 
the quality standards to other countries.
We hypothesise that the quality standards are also perti-
nent to professionals in nursing homes in other coun-
tries, even if regulatory and organisational conditions 
differ. The standards only specify which tasks are relevant 
to perform (eg, that nurses should forward their observa-
tions), but not how to perform the task exactly (eg, how to 
forward it). They are, therefore, generalisable to different 
types of organising care (internationally) and their imple-
mentation can be adapted to local needs. However, the 
selection of requirements rated to be clinically relevant 
may of course have been influenced by practical prob-
lems and challenges encountered in daily practice by the 
experts. Countries with similar healthcare systems and 
conditions may especially benefit from the application 
of our quality standards. For example, nursing homes in 
Belgium and Germany are also confronted with a high 
number of external family physicians involved in resident 
care.34 35 It is therefore plausible that our requirements 
will be especially relevant for these countries.
COnCluSiOnS
The quality standards describe specific minimal standards 
for five key topics for the safer and resident- oriented 
medication in nursing homes. For Switzerland, they are 
the first standards developed with a multistep, evidence- 
based method, and they reached very high consensus in 
the Delphi study. The quality standards are normative and 
describe what would be considered a ‘gold standard’ for 
safe medication processes. They are not quality indicators 
and do not measure outcome or processes. We hypothe-
sise that with their rigorous implementation, medication 
safety for nursing home residents may improve and inter-
professional collaboration will be enhanced. In a next 
step, the quality standards have to be implemented in 
practice and tested for practicability and effectiveness for 
a safe and resident- oriented medication.
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